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Abstract: Micafungin, like other members of the echinocandin class, has a unique mechanism of 
action that inhibits the synthesis of 1,3-β-D glucans in the fungal cell wall. It has been approved for 
treatment of esophageal candidiasis, invasive candidiasis including candidemia, and for prophylaxis 
of Candida infections in patients undergoing hematopoietic stem cell transplantation. Although 
efficacy and safety have also been demonstrated in pediatric populations, micafungin is approved for 
this indication in Europe and Japan, but not in the United States. It has demonstrated activity against 
Candida spp. including those that are azole-resistant as well as Aspergillus and a few other clinically 
important molds. It is administered intravenously as a once daily infusion and does not require dose 
adjustments for renal or moderate hepatic dysfunction. Its safety record, favorable tolerability profile, 
and few drug interactions make it an important agent for the treatment of invasive fungal infections.
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Introduction
The echinocandins are the newest class of antifungal agents to be approved for the 
treatment of invasive fungal infections. Caspofungin was the first to gain approval 
followed by micafungin and then anidulafungin. These compounds have a unique 
mechanism of action targeted to the fungal cell wall; therefore their toxicity profile 
is quite favorable. They demonstrate potent activity in vitro and in vivo against all 
Candida species, as well as activity against Aspergillus species and select less common 
fungal pathogens, such as Paecilomyces and Penicillium. Of the echinocandin class, 
caspofungin has been approved for the broadest array of indications including invasive 
candidal infections, candidemia, empiric therapy in febrile neutropenia, and as 
salvage therapy for invasive aspergillosis. Micafungin has been specifically approved 
for candidemia, invasive candidal infections, and as antifungal prophylaxis prior to 
hematopoietic stem cell transplant. These drugs may be used as single agent therapy 
for these infectious processes and may be considered as a component of combination 
antifungal therapy for more serious yeast or mold infections. In this review, we will focus 
on micafungin, discussing the chemistry, mechanism of action, efficacy, pharmacology, 
and safety, with a particular focus on the clinical trial data with this compound.
Chemical structure, mechanism  
of action, and resistance
Micafungin, formerly known as FK463, is a semisynthetic derivative of FR901370, 
a natural compound isolated from culture broth of Coleophoma empedri.1 It is a water Drug Design, Development and Therapy 2009:3 296
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soluble cyclic hexapeptide with a fatty acyl side chain, similar 
in structure to the other echinocandins.2 Micafungin is a 
noncompetitive inhibitor of the formation of 1,3-β-D glycan 
synthase, an enzyme unique to fungi that is necessary for the 
production of 1,3-β-D glucan, which is an integral component of 
the fungal cell wall necessary to maintain cell shape and osmotic 
stability.3 Micafungin exhibits fungicidal activity against 
Candida species (spp.), but is fungistatic against Aspergillus 
spp. This differential activity is potentially explained by wider 
distribution 1,3-β-D glucan in the cell wall of Candida spp. 
than that of Aspergillus spp. Micafungin, as well as the other 
echinocandins, exerts no activity against the zygomycetes and 
Cryptococcus, which lack 1,3-β-D glucan in their cell walls.4
The antifungal effect of micafungin on Candida spp. 
was studied by observing changes in cell morphology and 
structure using both light and electron microscopy.5 After a 
short duration of exposure to micafungin, C. albicans cells 
showed abnormal swelling, irregular shape, and increased size 
by light microscopy, and deformation of contour, abnormal 
septum formation, and cell wall thinning especially at sites 
of active budding by electron microscopy. A lesser effect was 
noted on the cell membrane and cytomplasmic organelles. 
These results suggest that micafungin primarily affects 
normal cell wall formation in growing Candida cells. Similar 
studies with Aspergillus fumigatus revealed disruption of 
hyphal walls with eventual hyphal collapse and damage to 
membranous structures including the cell membrane, nuclear 
membrane, and endoplasmic reticula.6
Micafungin is also active against Candida biofilms and 
has demonstrated reduced adherence of both azole-susceptible 
and azole-resistant C. albicans strains to epithelial cells.7 
Another study showed comparable activity of micafungin 
to both biofilm and planktonic forms of C. albicans and 
C. parapsilosis.8 These studies suggest that micafungin may 
have a role in treating Candida catheter-related infections, 
in which biofilm formation is pertinent to clinical infection. 
Micafungin also been enhances the oxidative burst effect of 
neutrophils in in vitro studies with Candida pseudohyphae.9
Acquired resistance or reduced susceptibility to micafungin 
and the other echinocandins has been reported only rarely, with 
the majority of cases associated with mutations in the FKS1 
genes.10,11 These mutations in Candida spp. lead to altered 
drug binding and thus cross-resistance to all echinocandins. 
No resistance data in Aspergillus species are available.
Pharmacokinetics
Micafungin has a large molecular weight and is not 
well-absorbed orally. Pharmacokinetics of intravenous 
administration have been studied in healthy volunteers as 
well as ill patients with presumed/proven fungal infections. 
Micafungin exhibits a linear, dose-dependent relationship, 
with increasing doses resulting in proportionate increases in 
mean maximum serum concentrations (Cmax) and area under 
the concentration (AUC)-time curve from 0 to 24 hours 
(AUC0–24).12 Similar linear kinetics have also been observed 
in pediatric patients.13
In healthy adult volunteers, a single 100 mg dose of 
micafungin has a mean half-life of 14.6 hours and is 99% 
protein-bound.14 Micafungin is hepatically metabolized 
to inactive metabolites and is excreted primarily through 
the biliary system into the feces, with 1% excreted 
unchanged in the urine. Micafungin is not metabolized via 
the CYP450 system. When studied in patients with moderate 
hepatic dysfunction (Child–Pugh score 7–9), a significantly 
lower AUC0–24, with no difference in the Cmax, was found, 
as compared with healthy adults.14 No differences in 
pharmacokinetics were found in patients with moderate renal 
dysfunction (creatinine clearance 30 mL/min).
In vitro activity
Potent in vitro activity of the echinocandins has been 
demonstrated for most Candida spp. including those with 
high-level azole resistance.1,15–17 In one study of 2000 Candida 
bloodstream isolates, most species (C. albicans, C. glabrata, 
C. tropicalis, and C. dubliniensis) exhibited minimum 
inhibitory concentrations (MICs) of 0.03 to 0.06 µg/mL.15 
The MICs for C. krusei and C. lustitaniae were slightly 
higher (0.6–2.0 µg/mL), with C. parapsilosis having the 
highest MIC (1–2 µg/mL). Findings have been similar for 
C. guilliermondii (MIC 0.125 µg/mL).1 In this latter study, 
azole-resistant strains demonstrated no cross-resistance 
to micafungin, and overall, the isolates had lower MICs 
to micafungin than to amphotericin B, fluconazole, and 
itraconazole. The Clinical and Laboratory Standards Institute 
(CLSI) has recently established susceptibility breakpoints for 
echinocandins against Candida spp. A MIC  2 µg/mL for 
all three echinocandin agents is classified as susceptible, and 
a value 2 µg/mL is considered non-susceptible.18 Time-kill 
assays have also shown fungicidal activity for most Candida 
strains.1,19 A post-antifungal effect has also been shown, and 
may be enhanced with higher drug concentrations.19
Micafungin also has potent in vitro activity against 
Aspergillus spp., including A. fumigatus, A. flavus, A. niger, 
A. versicolor, A terreus, and A. nidulans.1,20 MIC ranges 
of 0.0078–0.0156 ug/mL have been reported against these 
Aspergillus spp., however standard susceptibility breakpoints Drug Design, Development and Therapy 2009:3 297
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for the echinocandins against molds have not been 
established.1 The minimum effective concentration (MEC), 
which is the minimum concentration noted to produce 
short and aberrant hyphal branching under the microscope, 
has been proposed as an alternative measure, and has been 
reported as 0.125 µg/mL for several Aspergillus spp., 
including A. fumigatus, A. flavus, A. niger.20 In vitro activity 
has also been demonstrated against Paecilomyces and 
Penicillium,21 as well as the mycelial forms of Histoplasma 
capsulatum, Blastocystis dermatitidis, and Coccidiodes 
immitis.22 The clinical significance of the latter finding 
is unclear, as the yeast forms of the dimorphic fungi 
are the pathogenic forms implicated in causing human 
disease. Micafungin has no activity against Cryptococcus, 
Trichosporon, Fusarium, Pseudoallescheria, Alternaria, 
zygomycetes, or Scedosporium.1,4,21
Clinical trials
Micafungin is approved for treatment of esophageal 
candidiasis, invasive candidiasis and candidemia, and for the 
prophylaxis of Candida infections in individuals undergoing 
hematopoietic stem cell transplant (HSCT). This drug has 
not been studied in candidal endocardititis, osteomyelitis, or 
meningitis. It also has been shown to have efficacy in the treat-
ment of invasive aspergillosis, but it has not been approved 
for this indication. Although micafungin has been studied in 
both adults and children, in the United States it is currently 
approved for use only in adults. However, in Europe and 
Japan, it has a pediatric indication for treatment of invasive 
candidiasis, prophylaxis in HSCT, treatment of Aspergillus 
infections, and empiric therapy for febrile neutropenia.
esophageal candidiasis
The efficacy of micafungin for the treatment of esophageal 
candidiasis was established in an open-label, dose-range trial 
and two prospective, randomized, double-blind clinical trials. 
The first study to demonstrate efficacy of micafungin for the 
treatment of esophageal candidiasis was an open-label study 
to determine dosing and safety in 120 HIV patients with 
endoscopically proven esophageal candidiasis.23 Patients 
were randomly assigned to receive 12.5 mg, 25 mg, 50 mg, 
75 mg, or 100 mg of micafungin daily for planned treatment 
duration of 14 days. The primary endpoint was clinical 
response, defined by cure or improvement in clinical signs 
and symptoms, and the secondary endpoint was improvement 
in esophageal mucosal lesions. The efficacy analysis 
included 84 patients that had documented positive cultures 
for Candida and received at least 1 dose of study drug. 
A dose-dependent relationship was found, with clinical 
improvement seen with all doses, and those patients receiving 
100 mg achieving a 95% cure rate. Patients receiving 75 or 
100 mg had a 2- to 3-fold greater reduction in endoscopic 
mucosal lesions at the end of treatment as compared to the 
lower dose groups. Response was rapid, with most patients 
experiencing considerable improvement within the first 3 to 
5 days. No serious renal, hepatic, or drug-related reactions 
were reported.
The efficacy of micafungin as compared to fluconazole 
for the treatment of esophageal candidiasis was established 
in 2 randomized, double-blind trials. In the first, 245 adult 
HIV patients with esophageal candidiasis confirmed by 
endoscopy and culture were randomized to receive either 
micafungin (50, 100, or 150 mg per day) or standard-dose 
fluconazole (200 mg per day) for 14 to 21 days.24 The 
primary endpoint was endoscopic cure rate at the end of 
treatment. In the intent-to-treat analysis of 245 patients, the 
cure rate for micafungin was found to be dose-dependent, 
with the 50, 100, and 150 mg groups achieving cure rates 
of 69%, 77%, and 90%, respectively (P = 0.024). The cure 
rate for fluconazole was 87%. Overall, the endoscopic 
cure rates were similar between the combined micafungin 
100 and 150 mg group (84%) and the fluconazole group 
(87%) (95% CI for the cure rate −14 to 7.7). Microbiologic 
cure was achieved in 35.1%, 78.3%, and 57.1% for the 
micafungin 50 mg, 100 mg, and 150 mg groups, respectively. 
Microbiologic cure was 67.3% in the fluconazole group. 
During the 2-week post-treatment period, 9 patients who 
had received micafungin were considered to have relapsed 
and either developed worsening symptoms or were treated 
with non-prophylactic doses of antifungal agents, although 
only 1 person experienced reversion to baseline clinical 
symptoms. No patients in the fluconazole arm experienced 
relapse. Adverse event rates were comparable among the 
two arms. In the second randomized, double-blind study, 
523 predominantly HIV-positive adults with symptomatic 
and endoscopically confirmed esophageal candidiasis were 
randomized to micafungin 150 mg per day or fluconazole 
200 mg per day, for a minimum of 14 days.25 The primary 
endpoint was endoscopic cure. In the intent-to-treat analysis 
of 518 patients who received at least 1 dose of study drug, 
there was no difference in efficacy, with endoscopic cure 
rates of 88% in both groups (95% CI –5.9 to 5.3). Relapse 
rates through 4 weeks after treatment were also similar 
(15.2% in the micafungin arm, 11.3% in the fluconazole 
arm [P = 0.257]). There was also no difference in incidence 
of adverse events between the two groups. These studies Drug Design, Development and Therapy 2009:3 298
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indicated that micafungin was safe and as effective as 
fluconazole for the treatment of esophageal candidiasis.
Candidemia, acute disseminated 
candidiasis, Candida peritonitis  
and abscesses
Micafungin has also been approved for the treatment 
of candidemia and other forms of invasive candidiasis. 
Micafungin was first studied for the treatment of candidemia 
in an open-label, noncomparative, international trial of 
148 pediatric and adult patients.26 Patients with newly 
diagnosed candidemia and less than 48 hours of prior 
antifungal therapy received micafungin, 50 mg/day for 
C. albicans infections and 100 mg/day for non-albicans 
infections. Pediatric patients weighing 40 kg received 
doses of 1 mg/kg/day for C. albicans and 1 to 2 mg/kg/day 
for non-albicans infections. Patients with refractory disease 
could also be enrolled if they had failed prior antifungal 
therapy (no response after at least 5 days of therapy), and 
received micafungin alone or in combination with their prior 
antifungal agent. The dose of micafungin could be increased 
in 50-mg increments (1 mg/kg in pediatric patients) after 
5 days of therapy. Treatment duration was a minimum of 
5 days and maximum of 6 weeks. The primary endpoint was 
complete or partial response at the end of therapy, based on the 
investigator’s overall assessment of clinical and mycological 
response. The per-protocol set included 126 patients who 
received at least 5 doses of study drug, including 72 newly 
diagnosed patients and 54 refractory patients (25 receiving 
micafungin, 29 treated with combination therapy). The 
overall treatment success rate was 84% (105/126) including 
88% (63/72) in the newly diagnosed patients, 76% (19/25) 
in refractory patients receiving monotherapy, and 79% 
(23/29) in refractory patients treated with combination 
therapy. Infections with non-albicans species occurred 
in 64% of patients. High success rates were seen in the 
most common Candida spp. including C. albicans (85%), 
C. glabrata (94%), C. parapsilosis (86%), C. tropicalis 
(83%), and C. krusei (64%). Overall, serious adverse events 
were rare and the drug was generally well tolerated. In this 
study, micafungin showed promising efficacy as therapy for 
newly diagnosed or refractory candidemia caused by both 
C. albicans and non-albicans species.
In another randomized, double-blind, multi-center, 
noninferiority trial, micafungin was compared to liposomal 
amphotericin B in the treatment of candidemia and invasive 
candidiasis.27 A series of 531 adults with invasive candidal 
infections with positive cultures from either blood or 
another sterile site were randomized to receive micafungin 
(100 mg/day) or liposomal amphotericin B (3 mg/kg/day) for 
a minimum of 14 days. The primary endpoint was the overall 
treatment success rate based on both clinical and mycological 
responses. The per-protocol analysis group consisted of 
392 patients who had a confirmed candidal infection and 
received five doses of the study drug. Treatment success 
was achieved in 90% (181/202) of the micafungin group 
and 90% (170/190) of the liposomal amphotericin B group 
(95% CI –5.9 to 6.2). Infections were caused by C. albicans 
and non-albicans species in both arms, and treatment 
success was comparable against all Candida species in both 
arms. There were fewer overall and serious adverse events 
reported in the micafungin group, with significant reductions 
in the rates of hypokalemia, elevated serum creatinine, and 
infusion-related reactions with micafungin as compared to 
amphotericin B (P  0.5).
A second substudy was performed with pediatric patients 
(16 years of age) with documented invasive candidiasis 
in which patients were randomized to treatment with either 
micafungin (2 mg/kg/day) or liposomal amphotericin 
B (3 mg/kg/day).28 The primary endpoint was overall 
treatment success rate based on both clinical and mycological 
responses. By the similarly defined per-protocol analysis, 
treatment success was achieved in 85% (35/41) and 88% 
(37/42) of cases in the micafungin and liposomal amphotericin 
B groups, respectively (95% CI –16.4 to 12.7). Both therapies 
were well tolerated, with similar overall and serious adverse 
event rates. However, there were fewer adverse events leading 
to discontinuation of treatment in the micafungin group 
(3.8%) than the amphothericin group (16.7%) (P = 0.05). 
These studies demonstrated the safety and efficacy of 
micafungin for the treatment of invasive candidiasis in both 
adult and pediatric populations.
In a subsequent randomized, double-blind, noninferiority 
study, micafungin was compared to caspofungin for the 
treatment of candidemia or invasive candidiasis.29 A total 
of 595 adults with documented candidemia or positive 
candidal culture from a sterile site were randomized to one 
of three therapies: micafungin 100 mg/day, micafungin 
150 mg/day, or caspofungin, 70 mg on day one followed 
by 50 mg/day, all for a minimum 14 days of therapy. The 
primary endpoint was treatment success, defined as clinical 
and mycological success at the end of therapy. Efficacy data 
based on 578 patients with documented candidal infection 
who received at least 1 dose of study drug comprised the 
modified intention-to-treat analysis. Treatment success was 
achieved in 76% (146/191) of patients treated with 100 mg of Drug Design, Development and Therapy 2009:3 299
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micafungin, 71% (142/199) of those receiving 150 mg of 
micafungin, and 72% (136/188) treated with caspofungin. 
Again, both C. albicans and non-albicans infections were 
studied, and the overall response rates were similar across 
all Candida spp. Adverse events were similar among all 
groups. The authors concluded that micafungin at a dose 
of either 100 or 150 mg/day was non-inferior to and as 
safe as caspofungin in the treatment of invasive candidal 
infections.
Antifungal prophylaxis for hematopoietic 
stem cell transplant recipients (HSCT)
Micafungin has also been approved for antifungal prophylaxis 
for patients undergoing HSCT.30 In a randomized, double-blind, 
comparative, phase III trial, 889 patients were randomized to 
micafungin 50 mg/day (or 1 mg/kg for body weight 50 kg) or 
fluconazole 400 mg/day (or 8 mg/kg for body weight 50 kg) 
for prophylaxis of invasive fungal infections. Prophylactic 
therapy was initiated by day 2 of the conditioning phase, 
and was continued until one of the following criteria was 
reached: day 5 after engraftment (defined as rise in absolute 
neutrophil count to 500 cells/mm3), day 42 post-HSCT, 
development of a proven, probable, or suspected invasive 
fungal infection, or discontinuation due to adverse toxicity. 
The primary endpoint was treatment success, defined as the 
absence of proven, probable, or suspected systemic fungal 
infection at the end of prophylactic therapy, as well as the 
absence of proven or probable systemic fungal infection at 
the end of the four week post-treatment period. Median treat-
ment duration was 18 days. The modified intention-to-treat 
analysis was based upon 882 of the 889 enrolled patients who 
received at least 1 dose of study drug. The overall treatment 
success rate was significantly higher with micafungin than 
with fluconazole (80% [340/425] vs 74% [336/457], respec-
tively [P = 0.03]). Adverse events were similar among the two 
groups, although patients receiving micafungin tended to dis-
continue therapy because of adverse events less often (4%, as 
compared to 7% with fluconazole, P = 0.058). Although not 
statistically significant, there was an increased frequency 
of breakthrough proven or probable Aspergillus infections 
in the fluconazole arm compared with micafungin (7 vs 1 
case, respectively, P = 0.071). One limitation of the study 
was that micafungin was continued only through 5 days after 
engraftment or for a maximum of 42 days, and patients were 
followed through day 28 post-treatment; therefore patients 
who develop late-onset, invasive mold infections would not 
be included. This was the first study to compare micafungin 
to fluconazole for antifungal prophylaxis for HSCT patients, 
and demonstrated the superior efficacy of micafungin, with 
comparable safety to fluconazole.
A recent Japanese study evaluated a higher dose of 
micafungin for the prevention of invasive fungal infections in 
HSCT recipients.31 Micafungin, 100 mg/day, was administered 
to 44 HSCT patients for antifungal prophylaxis. These 
patients were then compared to 29 historical controls given 
prophylactic fluconazole 400 mg/day. The primary endpoint 
was treatment success, defined as the absence of proven, 
probable, or possible invasive fungal infection through day 21 
post-HSCT. The median duration of treatment for micafungin 
and fluconazole were 36 and 34 days, respectively. The 
efficacy analysis included 41 patients receiving micafungin. 
Treatment success was achieved in 88% (36/41) of the 
patients receiving micafungin compared to 66% (19/29) of 
patients receiving fluconazole (P = 0.038). Although not 
a prospective, comparative, randomized trial, the 100 mg 
dose of micafungin for antifungal fungal prophylaxis in this 
population was shown to be safe and efficacious.
Another recent prospective, randomized, open-labeled 
study conducted in Japan compared micafungin 150 mg/day 
to fluconazole 400 mg/day for antifungal prophylaxis in 
104 adult HSCT patients.32 The primary outcome was 
treatment success, defined as the absence of proven, probable, 
or suspected invasive fungal infection at the end of therapy and 
the absence of proven or probable systemic fungal infection at 
the end of the 4-week post-treatment period. In the modified 
intention-to-treat analysis of the 100 patients who received 
at least one dose of study drug, the efficacy of micafungin 
was comparable to fluconazole with treatment success rates 
of 94% (47/50) vs 88% (44/50), respectively (P = 0.295). 
The number of patients requiring empiric antifungal therapy 
was 4% in the micafungin group compared to 12% in the 
fluconazole group. Although the study was small and not pow-
ered to measure differences in success rates, it suggested that 
150 mg/day of micafungin was safe and had similar efficacy 
to fluconazole for HSCT antifungal prophylaxis.
Alternative uses of micafungin
Febrile neutropenia
Micafungin has also been studied in the treatment of febrile 
neutropenia that is unresponsive to empiric, broad-spectrum 
antibacterial therapy. Amphotericin derivatives have 
typically been the standard of care in this clinical scenario, 
although they may be associated with multiple adverse 
effects including electrolyte abnormalities, renal failure, 
and infusion-related reactions. Micafungin was studied 
in a prospective, non-randomized, open-label study at a Drug Design, Development and Therapy 2009:3 300
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single center in Japan.33 In this study, 31 adults with acute 
leukemia and febrile neutropenia were empirically started 
on broad-spectrum antibiotics. Indications for initiation of 
micafungin therapy were a positive fungal culture or serum 
assay for β-D glucan, persistent fevers after five days of 
antibiotic therapy, or recurrent fevers. Micafungin doses 
ranged from 50 to 150 mg/day, although three patients had 
doses of 200 or 300 mg/day. The primary endpoint was 
treatment success, defined as fever defervescence during 
the neutropenic period and cure of any baseline invasive 
fungal infections, if present. Treatment failure was defined as 
breakthrough fungal infection, discontinuation of micafungin 
because of adverse event or lack of efficacy, required 
addition of other antifungal drugs, or death from any cause. 
Therapy was continued until the absolute neutrophil count 
rose was 500 cells/mm3 and the patient was afebrile for 
48 hours. If the patient remained neutropenic, therapy could 
be discontinued if the patient was afebrile for at least five 
days and was clinically stable. Median duration of micafungin 
treatment was 9.5 days. The efficacy analysis included 18 
patients who fulfilled the protocol criteria and received 
micafungin therapy. Treatment success was achieved in 
78% (14/18) of the patients. Overall, most reported adverse 
events were minor and included elevated liver function tests, 
hypokalemia, and skin rash. Only one patient required drug 
discontinuation due to refractory hypokalemia.
In another prospective, open-labeled, single-center trial 
with the same inclusion criteria and primary endpoint, the 
efficacy and safety of micafungin for febrile neutropenia 
in hematologic malignancy patients was assessed.34 The 
efficacy analysis included 23 of the 32 enrolled patients who 
fulfilled the inclusion criteria and received micafungin for 
a mean duration of 17.8 days. The overall treatment success 
rate was 74% (17/23). Micafungin doses ranged from 50 to 
300 mg/day, and those treated with at least 100 mg/day tended 
to have a better outcome. Adverse events, specifically elevated 
liver function tests, were reported in 5 (22%) of patients, 
with none resulting in discontinuation of micafungin therapy. 
Although small, these studies suggested that micafungin 
may be safe as well as efficacious for empiric treatment of 
febrile neutropenia.
invasive aspergillosis
Micafungin has been studied in patients with chronic 
immunosupression or prolonged neutropenia who developed 
invasive fungal infection, including aspergillosis. In a 
prospective, open-label, multicenter Japanese trial, the 
efficacy of micafungin was evaluated in adults with 
deep-seated fungal infections, including pulmonary 
aspergillosis, chronic necrotizing pulmonary aspergillosis, 
pulmonary aspergilloma, candidemia, and esophageal 
candidiasis.35 A total of 70 patients were enrolled and received 
micafungin 12.5 to 150 mg/day for up to 56 days. The 
primary endpoint was success in overall clinical response, 
based upon clinical, mycologic, and serologic response, and 
improvement in diagnostic imaging abnormalities. For the 
efficacy analysis, which included 54 patients who received 
at least 7 doses of micafungin, overall successful response 
rates were 60% (6/10) for pulmonary aspergillosis, 67% (6/9) 
for chronic necrotizing pulmonary aspergillosis, and 55% 
(12/22) for pulmonary aspergilloma. Therapy of candidemia 
and esophageal candidiasis was also successful, in 100% 
(6/6) and 71% (5/7) of patients, respectively.
Micafungin has also been studied alone and in combination 
with other antifungal agents for the treatment of invasive 
aspergillosis (IA) in a prospective, open-label, multinational, 
non-comparative trial.36 Both adults and pediatric patients 
who met diagnostic criteria for proven or probable IA (only 
pulmonary aspergillosis could be considered probable) were 
enrolled. Of the 331 patients, 225 who met diagnostic criteria 
and received at least 1 dose of micafungin were analyzed 
as part of the modified full analysis set. The majority of 
patients had undergone HSCT, received chemotherapy for 
hematologic or solid tumor malignancies, or undergone 
solid organ transplantation. The primary treatment group 
consisted of patients who were newly diagnosed and had 
received 48 hours of antifungal therapy, while the salvage 
group consisted of patients who been treated for 72 hours 
and experienced disease progression or lack of improvement. 
Patients in both groups received micafungin, either as a single 
agent or in combination with other antifungal therapy. Patients 
received an initial micafungin dose of 75 mg/day (1.5 mg/kg 
for patients weighing 40 kg), which could be increased by 
75 mg (1.5 mg/kg) increments after 7 days of therapy. The mean 
duration of treatment was 53.6 days. A favorable response at 
the end of therapy, defined as complete or partial response, 
was seen in 36% (80/225) of all patients. Of those receiving 
single agent micafungin, a favorable response was seen 
in 50% (6/12) of patients receiving primary treatment and 
41% (9/22) in the salvage therapy group. The corresponding 
results for the micafungin combination therapy were 
29% (5/17) in the primary treatment group and 35% (60/174) 
in those receiving salvage therapy. In this study, the use of 
micafungin was safe and showed promising efficacy.
The use of micafungin alone and in combination with 
other antifungal therapy was then examined in the subset Drug Design, Development and Therapy 2009:3 301
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of 98 HSCT recipients with IA from this trial.37 Patients 
were categorized as either newly diagnosed (48 hours of 
antifungal therapy) or refractory disease after 72 hours of 
systemic antifungal therapy. The majority of patients received 
combination antifungal therapy. A partial or complete 
response was seen in 26% (25/98) of patients. Response rates 
were 38% (3/8) in the monotherapy group (1 newly diagnosed 
and 2 patients with previous antifungal toxicity with a 
favorable response), and 24% (22/90) in the combination 
group (1 newly diagnosed and 21 in the refractory group with 
a favorable response). The overall response rate was lower in 
this HSCT subset, likely related to high rates of graft vs host 
disease (GVHD), prolonged neutropenia, and more cases of 
refractory infection. Nonetheless, the use of micafungin was 
safe and provided some efficacy alone or in combination for 
the treatment of IA.
Safety and adverse events
Overall, the use of micafungin has proven to be safe and 
well-tolerated, similar to the other echinocandins. Significant 
adverse events infrequently reported have included 
hypersensitivity and anaphylactic reactions, intravascular 
hemolysis and hemolytic anemia, and hepatic dysfunction 
with hyperbilirubinemia and/or acute hepatitis (package 
insert). The more common less severe side effects include 
diarrhea, nausea, and vomiting, as well as fever and electrolyte 
abnormalities. Lastly, a black-box warning for this agent 
has been issued in Europe, based upon an increased number 
of liver tumors observed in rat models. No such black-box 
warning has been included in the US label.
The pharmacokinetics, maximum tolerated dose, 
and safety of micafungin have been studied in several 
trials. In one series of 74 adult HSCT patients, antifungal 
prophylaxis consisted of fluconazole with either micafun-
gin or placebo.12 Micafungin, in doses ranging from 12.5 to 
200 mg/day, was administered to 62 patients. The maximum 
tolerated dose was not reached, and adverse events were 
few in number. The most common side effects included 
headache (7%), arthralgias (7%), hypophosphatemia (4%), 
insomnia (4%), and rash (4%). Mean kidney and liver function 
tests were similar at the end of treatment in all groups, but 
4 patients treated with micafungin had liver function tests 
2.5 times the upper limit of normal (2 had elevated alanine 
aminotransferse levels and 2 had elevated total bilirubin). 
No interactions were detected between micafungin and 
fluconazole. A similar dose escalation study was conducted in 
77 pediatric patients with febrile neutropenia.13 In this study, 
micafungin was started at the onset of fever along with broad 
spectrum antibiotics, in doses ranging from 0.5 to 4 mg/kg. 
Nine (12%) patients experienced an adverse event thought to 
be related to the study drug which included headache (n = 2), 
diarrhea (n = 2), and vomiting (n = 2). Kidney and liver 
function tests again remained unchanged from baseline.
Conclusion
Micafungin was the second drug in the echinocandin class 
approved in the United States and is active against Candida 
and Aspergillus spp. It has specifically been approved for 
use in treating esophageal candidiasis, invasive candidal 
infections and candidemia, and as anti-fungal prophylaxis 
prior to hematopoietic stem cell transplant in adult patients. 
Clinical trials have also demonstrated its efficacy in 
combination with other antifungal agents for the treatment 
of invasive Aspergillus infections. Although efficacy and 
safety has been demonstrated in pediatric populations, this 
agent is currently approved for the pediatric population only 
in Europe and Japan. Overall, micafungin has proven to be 
safe, well tolerated, and to have few drug interactions. Future 
direction should include additional studies for use alone 
and as a component of combination antifungal therapy for 
invasive and refractory mold infections.
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